文献类型：期刊文献

英文题名：Controlled release of gentamicin from gelatin/genipin reinforced beta-tricalcium phosphate scaffold for the treatment of osteomyelitis

作者：Wu, Tianyi[1,3];Zhang, Qingchun[2];Ren, Weiping[4];Yi, Xiang[3];Zhou, Zubin[1];Peng, Xiaochun[1];Yu, Xiaowei[1,3];Lang, Meidong[2]

机构：[1]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China;[2]E China Univ Sci & Technol, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China;[3]Nanjing Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Nanjing 210011, Jiangsu, Peoples R China;[4]Wayne State Univ, Coll Engn, Dept Biomed Engn, Detroit, MI USA

年份：2013

卷号：1

期号：26

起止页码：3304

外文期刊名：JOURNAL OF MATERIALS CHEMISTRY B

收录：;EI(收录号：20132916519761);WOS:【SCI-EXPANDED(收录号:WOS:000320272000008)】；

基金：The authors gratefully acknowledge the foundation supported by the National Natural Science Foundation of China (no. 81071487); the Social Development Program of Jiangsu Province, China (Grant no. BE2010744); Shanghai Postdoctoral Sustentation Fund, China (Grant no. 11R21414400); China Postdoctoral Science Foundation (Grant no. 20100480598); the Medical Scientific Research Foundation of Jiangsu Province, China (Grant no. H201008); the National Natural Science Foundation of China (no. 81201425).

语种：英文

外文关键词：Reinforcement - Controlled drug delivery - Transmission control protocol - Bacteria - Bone - Targeted drug delivery

摘要：Infection of the bone (osteomyelitis) remains one of the most challenging problems in the field of orthopedic surgery. The limitations of systemic antibiotics administration include undesired side effects, systemic toxicity, patient discomfort, and development of bacterial resistance. In this study, we developed a bactericidal gentamicin-doped beta-tricalcium phosphate (TCP) scaffold reinforced with a gelatin/genipin hydrogel (G-TCP). Our data showed that the gentamicin-doped G-TCP had a much longer drug releasing period, while the gentamicin was completely released from pure TCP cements (B-TCP) within one day. In addition, the release profile of G-TCP exhibited an initial burst followed by a zero-order release. One standard strain, Staphylococcus aureus (S. aureus, ATCC25923) was selected to evaluate the antibacterial activity and therapeutic effect of this scaffold. G-TCP significantly inhibited growth of S. aureus both in vitro and in vivo. In a rat osteomyelitis model, osteomyelitis could be totally cured after implantation of G-TCP for three weeks. We propose that the gelatin/genipin-gentamicin TCP scaffold represents one of the promising gentamicin releasing bone scaffolds in treating osteomyelitis.